Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016

  • ID: 3984532
  • Report
  • 42 pages
  • Global Markets Direct
1 of 5
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016

Summary

‘Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H2 2016’, provides in depth analysis on Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted pipeline therapeutics.

The report provides comprehensive information on the Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large)
- The report reviews Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Overview

Therapeutics Development

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Stage of Development

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Therapy Area

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Indication

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Companies

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Products under Development by Universities/Institutes

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Companies Involved in Therapeutics Development

AbbVie Inc

Ascentage Pharma Group Corp Ltd

Takeda Pharmaceutical Company Limited

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Drug Profiles

ABT-737 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-1252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

navitoclax dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rottlerin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WEHI-539 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Dormant Projects

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Discontinued Products

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Featured News & Press Releases

Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539

Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology

May 16, 2005: Abbott Data Published In Nature Reveals A Promising New Approach In Cancer.

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by AbbVie Inc, H2 2016

Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Dormant Projects (Contd..2), H2 2016

Dormant Projects (Contd..3), H2 2016

Discontinued Products, H2 2016

List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Ascentage Pharma Group Corp Ltd
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll